Natriuretic Peptides in Valvular Heart Diseases

Heart Failure Clinics

Volumn 2, Issue 3, 2006, Pages 345-352

  Choure, Arti ^a   Tang, W H Wilson ^a   Mills, Roger M ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b SCIOS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE TYPE C;

AORTA VALVE REGURGITATION; AORTA VALVE STENOSIS; BLOOD EXAMINATION; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; ECHOCARDIOGRAPHY; HUMAN; MITRAL VALVE REGURGITATION; MITRAL VALVE STENOSIS; MYOCARDIAL DISEASE; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; REVIEW; RHEUMATIC HEART DISEASE; SCREENING TEST; VALVULAR HEART DISEASE;

HEART VALVE DISEASES; HUMANS; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDES;

EID: 33750927173     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2006.08.001     Document Type: Review

References (63)

1. Carabello B.A., and Crawford Jr. F.A. Valvular heart disease. N Engl J Med 337 (1997) 32-41
2. American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, et al. ACC/AHA 2006 Guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1988 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 114 5 (2006) e84-e231
3. Pellikka P.A., Nishimura R.A., Bailey K.R., et al. The natural history of adults with asymptomatic, hemodynamically significant aortic stenosis. J Am Coll Cardiol 15 (1990) 1012-1017
4. Watanabe M., Murakami M., Furukawa H., et al. Is measurement of plasma brain natriuretic peptide levels a useful test to detect for surgical timing of valve disease?. Int J Cardiol 96 (2004) 21-24
5. Maisel A.S., Krishnaswamy P., Nowak R.M., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347 (2002) 161-167
6. Morrison L.K., Harrison A., Krishnaswamy P., et al. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 39 (2002) 202-209
7. Nagaya N., Nishikimi T., Uematsu M., et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102 (2000) 865-870
8. Richards A.M., Nicholls M.G., Espiner E.A., et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 107 (2003) 2786-2792
9. Silvet H., Young-Xu Y., Walleigh D., et al. Brain natriuretic peptide is elevated in outpatients with atrial fibrillation. Am J Cardiol 92 (2003) 1124-1127
10. Kucher N., Printzen G., and Goldhaber S.Z. Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation 107 (2003) 2545-2547
11. Vasan R.S., Benjamin E.J., Larson M.G., et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA 288 (2002) 1252-1259
12. Redfield M.M., Rodeheffer R.J., Jacobsen S.J., et al. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. Circulation 109 (2004) 3176-3181
13. Levin E.R., Gardner D.G., and Samson W.K. Natriuretic peptides. N Engl J Med 339 (1998) 321-328
14. McKie P.M., and Burnett Jr. J.C. B-type natriuretic peptide as a biomarker beyond heart failure: speculations and opportunities. Mayo Clin Proc 80 (2005) 1029-1036
15. Yoshimura M., Yasue H., Morita E., et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 84 (1991) 1581-1588
16. Cao L., and Gardner D.G. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension 25 (1995) 227-234
17. Golbasy Z., Ucar O., Yuksel A.G., et al. Plasma brain natriuretic peptide levels in patients with rheumatic heart disease. Eur J Heart Fail 6 (2004) 757-760
18. Nagaya N., Nishikimi T., Okano Y., et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 31 (1998) 202-208
19. Yoshimura M., Yasue H., Okumura K., et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 87 (1993) 464-469
20. Arat-Ozkan A., Kaya A., Yigit Z., et al. Serum N-terminal pro-BNP levels correlate with symptoms and echocardiographic findings in patients with mitral stenosis. Echocardiography 22 (2005) 473-478
21. Davutoglu V., Celik A., Aksoy M., et al. Plasma NT-proBNP is a potential marker of disease severity and correlates with symptoms in patients with chronic rheumatic valve disease. Eur J Heart Fail 7 (2005) 532-536
22. Iltumur K., Karabulut A., Yokus B., et al. N-terminal proBNP plasma levels correlate with severity of mitral stenosis. J Heart Valve Dis 14 (2005) 735-741
23. Waldman H.M., Palacios I.F., Block P.C., et al. Responsiveness of plasma atrial natriuretic factor to short-term changes in left atrial hemodynamics after percutaneous balloon mitral valvuloplasty. J Am Coll Cardiol 12 (1988) 649-655
24. Hung J.S., Fu M., Cherng W.J., et al. Rapid fall in elevated plasma atrial natriuretic peptide levels after successful catheter balloon valvuloplasty of mitral stenosis. Am Heart J 117 (1989) 381-385
25. Ishikura F., Nagata S., Hirata Y., et al. Rapid reduction of plasma atrial natriuretic peptide levels during percutaneous transvenous mitral commissurotomy in patients with mitral stenosis. Circulation 79 (1989) 47-50
26. Nakamura M., Kawata Y., Yoshida H., et al. Relationship between plasma atrial and brain natriuretic peptide concentration and hemodynamic parameters during percutaneous transvenous mitral valvulotomy in patients with mitral stenosis. Am Heart J 124 (1992) 1283-1288
27. Fujiwara H., Ishikura F., Nagata S., et al. Plasma atrial natriuretic peptide response to direct current cardioversion of atrial fibrillation in patients with mitral stenosis. J Am Coll Cardiol 22 (1993) 575-580
28. Ledoux S., Dussaule J.C., Michel P.L., et al. Acute and delayed hormonal changes in mitral stenosis treated by balloon valvulotomy. Am J Cardiol 72 (1993) 932-938
29. Shang Y.P., Lai L., Chen J., et al. Effects of percutaneous balloon mitral valvuloplasty on plasma B-type natriuretic peptide in rheumatic mitral stenosis with and without atrial fibrillation. J Heart Valve Dis 14 (2005) 453-459
30. Razzolini R., Leoni L., Cafiero F., et al. Neurohormones in mitral stenosis before and after percutaneous balloon mitral valvotomy. J Heart Valve Dis 11 (2002) 185-190
31. Carabello B.A., Nolan S.P., and McGuire L.B. Assessment of preoperative left ventricular function in patients with mitral regurgitation: value of the end-systolic wall stress-end-systolic volume ratio. Circulation 64 (1981) 1212-1217
32. Enriquez-Sarano M., Tajik A.J., Schaff H.V., et al. Echocardiographic prediction of left ventricular function after correction of mitral regurgitation: results and clinical implications. J Am Coll Cardiol 24 (1994) 1536-1543
33. Crawford M.H., Souchek J., Oprian C.A., et al. Determinants of survival and left ventricularperformance after mitral valve replacement. Department of Veterans Affairs Cooperative Study on Valvular Heart Disease. Circulation 81 (1990) 1173-1181
34. Enriquez-Sarano M., Miller Jr. F.A., Hayes S.N., et al. Effective mitral regurgitant orifice area: clinical use and pitfalls of the proximal isovelocity surface area method. J Am Coll Cardiol 25 (1995) 703-709
35. Corin W.J., Sutsch G., Murakami T., et al. Left ventricular function in chronic mitral regurgitation: preoperative and postoperative comparison. J Am Coll Cardiol 25 (1995) 113-121
36. Brookes C.I., Kemp M.W., Hooper J., et al. Plasma brain natriuretic peptide concentrations in patients with chronic mitral regurgitation. J Heart Valve Dis 6 (1997) 608-612
37. Sutton T.M., Stewart R.A., Gerber I.L., et al. Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation. J Am Coll Cardiol 41 (2003) 2280-2287
38. Mayer S.A., De Lemos J.A., Murphy S.A., et al. Comparison of B-type natriuretic peptide levels in patients with heart failure with versus without mitral regurgitation. Am J Cardiol 93 (2004) 1002-1006
39. Detaint D., Messika-Zeitoun D., Avierinos J.F., et al. B-type natriuretic peptide in organic mitral regurgitation: determinants and impact on outcome. Circulation 111 (2005) 2391-2397
40. Tang W.H., Troughton R.W., Agler D.A., et al. B-type natriuretic peptide (BNP) predicts left ventricular response to surgery in patients with severe mitral regurgitation in asymptomatic patients with preserved left ventricular function. [abstract]. J Am Coll Cardiol 41 6, Suppl A (2003) A509
41. Cheng V., Kazanagra R., Garcia A., et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 37 (2001) 386-391
42. Enriquez-Sarano M., Tajik A.J., Schaff H.V., et al. Echocardiographic prediction of survival after surgical correction of organic mitral regurgitation. Circulation 90 (1994) 830-837
43. Tribouilloy C.M., Enriquez-Sarano M., Schaff H.V., et al. Impact of preoperative symptoms on survival after surgical correction of organic mitral regurgitation: rationale for optimizing surgical indications. Circulation 99 (1999) 400-405
44. Carabello B.A. Timing of valve replacement in aortic stenosis. Moving closer to perfection. Circulation 95 (1997) 2241-2243
45. Pellikka P.A., Nishimura R.A., Bailey K.R., et al. The natural history of adults with asymptomatic, hemodynamically significant aortic stenosis. J Am Coll Cardiol 15 (1990) 1012-1017
46. Ikeda T., Matsuda K., Itoh H., et al. Plasma levels of brain and atrial natriuretic peptides elevate in proportion to left ventricular end-systolic wall stress in patients with aortic stenosis. Am Heart J 133 (1997) 307-314
47. Prasad N., Bridges A.B., Lang C.C., et al. Brain natriuretic peptide concentrations in patients with aortic stenosis. Am Heart J 133 (1997) 477-479
48. Qi W., Mathisen P., Kjekshus J., et al. Natriuretic peptides in patients with aortic stenosis. Am Heart J 142 (2001) 725-732
49. Talwar S., Downie P.F., Squire I.B., et al. Plasma N-terminal pro BNP and cardiotrophin-1 are elevated in aortic stenosis. Eur J Heart Fail 3 (2001) 15-19
50. Gerber I.L., Stewart R.A., Legget M.E., et al. Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation 107 (2003) 1884-1890
51. Otto C.M. Aortic stenosis-listen to the patient, look at the valve. N Engl J Med 343 (2000) 652-654
52. Lim P., Monin J.L., Monchi M., et al. Predictors of outcome in patients with severe aortic stenosis and normal left ventricular function: role of B-type natriuretic peptide. Eur Heart J 25 (2004) 2048-2053
53. Weber M., Arnold R., Rau M., et al. Relation of N-terminal pro-B-type natriuretic peptide to severity of valvular aortic stenosis. Am J Cardiol 94 (2004) 740-745
54. Patel D.N., and Bailey S.R. Role of BNP in patients with severe asymptomatic aortic stenosis. Eur Heart J 25 (2004) 1972-1973
55. Bergler-Klein J., Klaar U., Heger M., et al. Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation 109 (2004) 2302-2308
56. Nessmith M.G., Fukuta H., Brucks S., et al. Usefulness of an elevated B-type natriuretic peptide in predicting survival in patients with aortic stenosis treated without surgery. Am J Cardiol 96 (2005) 1445-1448
57. Gerber I.L., Legget M.E., West T.M., et al. Usefulness of serial measurement of N-terminal pro-brain natriuretic peptide plasma levels in asymptomatic patients with aortic stenosis to predict symptomatic deterioration. Am J Cardiol 95 (2005) 898-901
58. Bonow R.O., Lakatos E., Maron B.J., et al. Serial long-term assessment of asymptomatic patients with chronic aortic regurgitation and normal left ventricular systolic function. Circulation 84 (1991) 1625-1635
59. Carabello B.A., Usher B.W., Hendrix G.H., et al. Predictors of outcome for aortic valve replacement in patients with aortic regurgitation and left ventricular dysfunction: a change in the measuring stick. J Am Coll Cardiol 10 (1987) 991-997
60. Gerber I.L., Stewart R.A., French J.K., et al. Associations between plasma natriuretic peptide levels, symptoms, and left ventricular function in patients with chronic aortic regurgitation. Am J Cardiol 92 (2003) 755-758
61. Ozkan M., Baysan O., Erinc K., et al. Brain natriuretic peptide and the severity of aortic regurgitation: is there any correlation?. J Int Med Res 33 (2005) 454-459
62. Eimer M.J., Ekery D.L., Rigolin V.H., et al. Elevated B-type natriuretic peptide in asymptomatic men with chronic aortic regurgitation and preserved left ventricular systolic function. Am J Cardiol 94 (2004) 676-678
63. Sandhu R., Tang W.H., Mills R., et al. Does the underlying etiology influence plasma B-type natriuretic peptide levels of patients with isolated chronic aortic regurgitation and preserved left ventricular function?. [abstract]. J Card Fail 10 4 Suppl (2004) S52